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Abstract
The incidence of radiation necrosis has increased secondary to combined 
modality therapy for brain tumors and stereotactic radiosurgery. The pathology 
of progressive brain radiation necrosis (RN) primarily includes inflammation and 
angiogenesis in which cytokines, chemokines, and vascular endothelial growth 
factors are upregulated. Combined multiparametric imaging, including lesional 
metabolism, spectroscopy, and blood flow, could enhance diagnostic accuracy 
compared with a single imaging study. Nevertheless, a substantial risk of bias 
restricts firm conclusions about the best imaging technique for diagnosing brain 
RN. Bevacizumab shows promising results of improving radiographic edema 
and post-gadolinium enhancement with associated symptomatic improvement. 
However, this was based on small double-blinded randomized controlled trials, 
which introduces a high risk of bias due to the small sample size despite the high-
quality trial design. Edaravone combined with corticosteroids also resulted in a 
more significant reduction in radiographic edema than corticosteroids alone but 
had no impact on reducing the enhancing lesion. There is a great need for further 
prospective randomized controlled trials (RCTs) to treat brain RN.
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1. Introduction
For years, radiation therapy (RT) has played a critical role in the treatment of 
primary brain tumors (PBT) and brain metastases (BM). Different techniques can 
be used depending on the clinical setting, including brachytherapy, fractionated 
stereotactic radiotherapy, and stereotactic radiosurgery. The use of RT in brain 
tumors has been related to improved progression-free survival as well as overall 
survival, especially in patients with high-risk low-grade gliomas [1]. As with dif-
ferent cytotoxic treatment approaches, the use of cranial irradiation comes with 
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the possibility of specific side effects known as radiation toxicity that can be acute 
(early toxicity) or late. Usually, early toxicity symptoms are reversible and treatable 
with proper supportive care; these symptoms include fatigue, headache, alopecia, 
dermatitis, nausea, and vomiting. Radiation necrosis (RN) is one of the leading late 
toxicity clinical manifestations. It usually occurs between 1–3 years after RT in the 
location that received the most radiation (tumor location) or a nearby area.
Clinical manifestations of RN will depend on the location of its development 
[2]. Signs and symptoms of focal neurologic deficits might occur, seizures are also 
present in approximately 20% of patients [3]. Depending on the region of the brain 
that is affected, different sets of symptoms might be present, including but not 
limited to motor deficits (2.9%), sensory deficits (1.3%), cognitive deficits (1%), 
speech deficits (1.3%), visual disturbances (0.6%), ataxia (1.6%) and general 
symptoms like headache (5%), nausea (1%) and hemorrhage (5%) [4]. This chapter 
will discuss the epidemiological features of RN, its risk factors, its pathophysiology, 
its diagnosis, and treatment.
2. Incidence of radiation necrosis
The current true incidence of RN is hard to estimate. According to Vellayappan 
et al., the incidence of this kind of toxicity might vary between 5–25% [5]. This 
broad range is mainly explained, but the different methodologies used in epide-
miological studies of RN in which its definition is not homogenous and only some 
studies have required histological confirmation, the studies’ follow-up can also 
provide different results. The kind of RT provided, the dosing, and the fraction-
ation of radiation might also impact the incidence of RN [6].
In a study made by Kohutek et al., the evidence of RN (including asymptomatic 
cases) was 25.8%, with a progressive increase in actuarial incidence regarding the 
time of evaluation as follows: 5.2% at six months after RT, 17.2% at 12 months, 
23% at 18 months and 34% at 24 months. The median time to the first diagnosis 
of RN was 10.7 months. In this study, the incidence of symptomatic RN was 11.8% 
at 12 months. Significant variability in diagnostic methods used in this study was 
seen, with some patients being diagnosed histologically, some via FDG-PET and 
others by MRI alone [7]. Another study conducted by Blonigen et al. analyzed RN 
in metastatic lesions after stereotactic surgery; a total of 63 patients with 173 lesions 
were studied. 14% of the lesions presented with RN, 10% were symptomatic. The 
individual factor related to a higher risk for RN, whether symptomatic or asymp-
tomatic, was an increased dose of radiation. The location of the lesion was not 
related to the development of RN of any kind [8].
Studies where pathological confirmation of RN was done reported the least inci-
dence, a clear example is an investigation made by Chin et al in which the reported 
incidence was only 7% [9]. This can be explained by a better sensitivity for histo-
pathological diagnosis and a greater rate of false positives in imaging techniques, as 
some other pathological mechanisms could resemble RN, including pseudoprogres-
sion, radiation-induced neoplasms, and vascular thrombotic events [10].
3. Pathophysiology of radiation necrosis
Vascular and white matter (myelinated tissue) injury have been stated as 
the genesis of RN. Since the second half of the 20th century, anecdotal clinical 
literature argued about the existence of delayed radiation-induced necrosis of the 
brain; however, scarce evidence was available regarding the exact mechanisms 
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of disease [11]. In the 1970s and 1980s, two main pathogenetic theories were 
formulated. The first one was the glial cell theory, in which radiation injury was 
presumed to induce damage of glial cells, specifically of oligodendrocytes, which 
will induce a cascade of events that will end in tissue necrosis [12]. The other 
theory stated that endothelial cell injury induced by radiation was the only cause 
explaining ischemia and further tissue necrosis. Different experimental studies 
performed in rats and dogs found data that supported both theories, and today we 
consider that RN arises as a multifactorial process in which glial cells, endothelial 
cells, and other cell types result injured by radiation generating different inflam-
matory and scarring processes that end in tissue necrosis [13–15].
Both theories are currently accepted as part of one single process in which 
vascular injury precedes glial cell damage. After brain tissue is exposed to radiation, 
avascular insult occurs within the first 24 hours, followed by parenchymal brain 
injury [16]. Reactive oxygen species develop because of ionizing radiation, leading 
to single- and double-stranded DNA damage. Regulatory cell mechanisms are acti-
vated and will drive the endothelium to cell cycle arrest and further apoptosis [17]. 
Ionizing radiation of more than 8 Gy will also induce activation of acid sphingo-
myelinase in endothelial cells [18, 19], leading to ceramide synthesis and ceramide-
induced apoptosis [20]. The injured tissue will also induce inflammation, producing 
the release of TNF-alpha [21], a molecule that has been shown to disrupt the blood–
brain barrier (BBB) in multiple physiological and pathological situations [22–24]. 
Increased expression of VEGF and ICAM-1 has also been shown [25, 26]. The result 
of this inflammatory cascades is the development of intravascular thrombi and fibri-
noid necrosis, leading to vessel lumen narrowing and further ischemia and necrosis 
and disrupting, even more, the BBB homeostasis [27], leading to cerebral edema and 
further demyelination [28]. Thus, vascular injury induces oligodendrocyte injury, 
but at the same time, the initial ionizing radiation can also directly damage glial 
cells, generating inflammation and gliosis. In the early-delayed phase of this process, 
edema might resemble tumor progression or pseudoprogression on imaging findings 
[29]. Research has also shown that ischemia-induced hypoxia in the perilesional area 
can induce HIF-α, which also induces VEGF expression generating angiogenesis of 
weak, leaky capillaries that aggravate edema, necrosis, and demyelination. Figure 1 
shows the pathophysiological characteristics for the development of the RN.
Figure 1. 
An illustration depicting RN pathophysiology is shown. When a patient receives radiation over a tumoral 
lesion, DNA damage occurs in glial and endothelial cells which will further lead to cell apoptosis. Vascular 
apoptosis leads to tissue ischemia and subsequent cerebral edema, processes that will facilitate BBB disruption 
with the further recruitment of inflammatory cells mediated by microglia. At the same time, increased 
expression of VEGF in response to hypoxia generates fragile neovessels that would leak plasma and would 
increase cerebral edema and BBB permeability.
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4. Risk factors related to radiation necrosis
As a result of different epidemiological, clinical, and genomic studies related to 
radiation-associated brain injury, different risk factors for RN have been identified.
4.1 Dose-volume interplay
The incidence of RN increases as dose and volume increase. Different studies 
have tried to find the ideal dose for different tumor diameters. Lesions of 20 mm 
or less can be safely treated with 24 Gy, 21–30 mm lesions with 18 Gy, and lesions 
between 31–40 with 15 Gy. The cumulative incidence of RN at 12 months for these 
measurements is 8% [30]. In the case of SRS, it has been demonstrated that the 
brain parenchyma that is irradiated with >10–12 Gy has a greater risk of developing 
RN. This risk is even higher when V10 > 10.5 cm3 or V12 > 7.9 cm3 [8].
4.2 Prior radiation exposure
Another essential risk factor for RN is prior radiation exposure, whether as 
whole-brain radiation therapy (WBRT) or SRS. A study performed by Sneed et 
al. showed that the risk of developing RN after SRS in a patient with prior SRS in 
the same lesion was 20% at one year, 4% when WBRT was the primary modality, 
and 8% when concurrent WBRT. When no history of prior irradiation, the risk 
was only 3% [31]. Andruska et al. studied the incidence of symptomatic RN in 75 
patients with brain metastases that received different doses in five fractions. With 
a median follow-up of 8 months, 14 patients were diagnosed with symptomatic 
RN; half of them were not previously exposed to brain radiation. However, in a 
subgroup analysis by dose received, patients with a history of prior intracranial 
irradiation only developed RN after 30 Gy, with the highest incidence when the 
dose was over 35 Gy [32].
4.3 Chemotherapy
Radiosensitization with cytotoxic agents is a common practice in the treatment 
of different tumors and metastatic diseases [33]. In the same study by Sneed et al., 
the use of capecitabine +5-fluorouracil was related to a higher incidence of RN [31]. 
Ruben et al. studied 426 patients who underwent intracranial RT for glioma treat-
ment; they found that patients who received subsequent chemotherapy signifi-
cantly increased the risk of RN (p = 0.001) [34].
4.4 Immunotherapy
Colaco et al. studied 180 patients who underwent SRS for brain metastases. 
Only 39 developed RN from this cohort, from which only 35% received immu-
notherapy (IT) (the agents received were anti-CD137, anti-CTLA4, anti-PD-1, 
interferon, and interleukin-2), from these patients, 12 had IT only, and 2 received 
IT plus targeted therapy. In the multivariate analysis, patients who received IT only 
were at higher risk of developing RN; however, the difference was not statistically 
significant (p = 0.06). Statistical significance was evidenced in the univariate 
analysis (p = 0.03) [35]. Another study by Martin et al. included 480 patients 
that underwent SRS for BMs. They found that the receipt of IT was associated 
with symptomatic RN (p = 0.04), with the association being robust in melanoma 
patients (p = 0.03) and being even more substantial in melanoma patients receiving 
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Ipilimumab (p = 0.01). As it is widely known, checkpoint inhibitors are pro-inflam-
matory. Therefore, it is biologically plausible that its use can exacerbate the myriad 
of pathological mechanisms underlying RN [36].
4.5 Tyrosine-kinase inhibitors
Juloori et al. performed a study of 326 patients with 912 renal cell carcinoma 
with BM that underwent SRS. The cumulative incidence of RN at 12 months was 
8%. It was found that the use of TKIs within 30 days from SRS was associated with 
a significantly increased 12-month cumulative incidence of RN (10.9% vs. 6.4%, 
p = 0.04) [37].
4.6 Brain location
Even though most studies did not find a correlation between brain location and 
RN risk, some observations by Flickinger et al. in arteriovenous malformations 
(AVMs) suggest that the frontal cortex is at higher risk of RN and that the brain-
stem seems to be more resistant to radiation. Superficial lesions might also be at less 
risk of RN than the deeper ones [38].
4.7 Histology
Specific histological subtypes of tumors might be related to an increased risk 
of RN. Miller et al. at the Cleveland Clinic studied 1979 patients with metastatic 
lesions that received intracranial irradiation. From this pool, 15% of patients pre-
sented with RN. Analysis by histological subgroups revealed that HER2-amplified 
status (p = 0.02), BRAF V600E mutational status (p = 0.04), lung adenocarcinoma 
histology (p = 0.02) and ALK rearrangements presence (p < 0.01) were associated 
with a greater risk of RN [39].
4.8 Planning target volume (PTV) margin
A higher PTV might be related to an RN’s increased risk. A study by Kirkpatrick 
et al. evaluated the risk of RN in 49 patients with 80 BMs. Patients were randomized 
to receive a 1 mm or 3 mm expansion of their gross tumor volume. Patients with 
the greater PTV (3 mm) had the highest risk of RN (p = 0.1); however, statistical 
significance was not reached as only six patients developed RN [40].
4.9 Intrinsic radiosensitivity
A possible genetic radiosensitivity might also underly some of the risk burdens 
of some patients that develop RN. One in vitro study evaluated the radiosensitivity 
of fibroblasts extracted from 5 patients with AVMs that did not develop RN com-
pared to those extracted from 2 patients that developed RN. The researchers found 
an increased sensitivity in the fibroblasts from the patients that had RN [41]. A 
recent genome-wide association study from China found that the RN of the tempo-
ral lobe was related to the presence of a particular single-nucleotide polymorphism 
in the CEP128 gene promoter related to radionecrotic temporal lobe injury. CEP128 
gene encodes the centrosomal protein 128 kDa, which interacts with multiple 
radiation-resistant genes and plays a crucial role in functional cilia. When this exact 




5. Radiation necrosis imaging
The pathology of progressive brain RN primarily includes inflammation and 
angiogenesis in which cytokines, chemokines, and vascular endothelial growth factors 
are upregulated [12, 15, 42, 43]. Distinguishing between RN and tumor progression 
is somewhat challenging on conventional imaging. Besides, obtaining tissue samples 
is invasive even in stereotactic biopsies, although pathological diagnosis remains the 
gold standard. Moreover, needle biopsy poses a risk of misdiagnosis because RN is 
typically a heterogeneous lesion with coexisting radiation necrosis and tumor cells 
[44]. Currently, RN is diagnosed by relatively less-invasive radiological examinations 
that evaluate the whole lesion, compared with needle biopsy. Strategies can be divided 
into two categories, the use of conventional radiological imaging [computed tomog-
raphy (CT) and magnetic resonance imaging (MRI)], and nuclear medicine studies 
[single photon emission CT (SPECT) and positron emission tomography (PET)] [45].
Brain RN may occur during therapy (acute injury), a few weeks to 3 months 
after therapy (early-delayed injury), or more than three months after treatment 
(late injury). After conventional radiotherapy, RN typically involves large areas 
of the brain and may not be amenable to surgery [46]. On the contrary, the injury 
secondary to radiosurgery tends to be restricted to the site of treatment and, con-
sequently, may respond well to surgical resection [47]. Computed tomography 
was found to be unreliable in this regard quite early [46, 48, 49]. The most cited 
MRI features are necrotic foci, contrast enhancement, and perilesional edema 
[50, 51]; Changes are most evident in T2-weighted and fluid-attenuated inversion 
recovery sequences. Unfortunately, these features are commonly present with 
recurrent tumors as well. Some MRI features have been thought to suggest radia-
tion necrosis in previous reports: contrast enhancement with ill-defined borders 
and little or no mass effect and a “Swiss cheese” or “soap bubble” pattern (“cut 
green pepper”). On the other hand, Dequesada et al. noted that gyriform lesions 
and edema with marginal or solid enhancement suggested at least some viable 
tumor, adding that a lesion quotient (LQ ) (which is the ratio of the nodule on 
T2 sequence to the total enhancing area on T1 sequence) of >0.6 was suggestive 
of tumor recurrence, while an LQ of <0.3 favored radiation necrosis alone [52]. 
Other authors however found this feature to be only 8% sensitive.
Years ago, some suggested that advanced imaging modalities might prove to be 
more reliable than MRI in the differential diagnosis of tumor versus necrosis. Taylor 
et al. [53] found that magnetic resonance spectroscopy (MRS) reliably identified 5 
of 7 patients with active tumor and 4 of 5 patients with radiation necrosis. Others 
have found that MRS reliably distinguished pure tumor from pure necrosis but that 
no values could distinguish mixed specimens [54, 55].
Almost two decades ago, Tsuyuguchi et al. found that methionine positron emis-
sion tomography had a sensitivity of 78% and a specificity of 100% for detecting 
recurrent tumor versus RN [56]. Subsequently, Belohlávek et al. found fluorodeoxy-
glucose PET to be insensitive but specific [57].
Since then, the use of MRS, MR perfusion, and PET has been consolidated as 
effective techniques to help increase diagnostic confidence. These techniques are 
discussed below.
5.1 MR perfusion
Viable tumor has intact vasculature and thus higher perfusion and blood 
volume than necrotic tissue. An increased relative cerebral blood volume (rCBV) 
based on dynamic susceptibility-weighted MRI has been used for differentiating 
tumor from necrosis [58]. Sugahara et al. prospectively studied 20 patients with 
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enhancing lesions after irradiation using gradient-echo dynamic susceptibility 
perfusion MRI and reported that a normalized rCBV value greater than 2.6 or less 
than 0.6 was always indicative of tumor recurrence and radiation necrosis, respec-
tively [59]. Later, Hu et al. reported rCBV of <0.71 as 92% sensitivity and 100% 
specificity for radiation necrosis, while another suggested an rCBV cutoff of <2.1 
(100% sensitivity and specificity) [58].
However, much of the published information is retrospective and inconsistent. 
Barajas et al. reported significant overlap in rCBV values and proposed using the 
percentage of signal-intensity recovery (PSR) [60]. Furthermore, rCBV values 
vary between machines, depend on the acquisition methods, and are confounded 
by signal-intensity pileup artifacts and susceptibility artifacts from blood and 
contrast pooling within the lesions. Intravoxel incoherent motion (IVIM) is another 
method that provides quantitative diffusion and perfusion measurements based on 
a diffusion-weighted imaging (DWI) MR acquisition. Compared with the combina-
tion of normalized CBV and ADC, adding IVIM to rCBV substantially improved the 
diagnostic accuracy for differentiating recurrent tumor and RN from 86% to 93% 
[61]. This data has been validated against gold standard histopathology [62].
5.2 MRS
MRS provides additional information on the metabolic composition within an 
area of tissue by comparing several metabolites’ relative concentrations. Ando  
et al. retrospectively studied 20 patients and found that a 1.5 threshold of choline-
to-creatine (Cho/Cr) ratio had a sensitivity of 64% (95% CI, 35–87%), and a 
specificity of 83% (95% CI, 36–100%) for the detection of glioma recurrence 
[63]. Traber et al. reported a series of 43 patients, with an increased choline peak 
(50% higher than contralateral tissue) which implies a sensitivity of 72% (95% CI, 
53–86%), and a specificity of 82% (95% CI, 48–98%) to distinguish tumor from 
RN; however, not in all patients there was a histopathological verification [64].
Besides, Lichy et al. tested multivoxel spectroscopy in a cohort of 24 patients 
with recurrent tumor suspicion and found that a Cho/Cr threshold ratio of 2.0 had 
87% sensitivity and 89% specificity for the detection of tumor recurrence in con-
trast to RN [65]. Furthermore, Plotkin et al. assessed prospectively 25 patients with 
suspected recurrent glioma versus radiation injury by single-voxel MRS at 3 Tesla. 
They reported that a combined diagnostic threshold of choline-to N-acetyl aspar-
tate (NAA) of 1.17 and Cho/Cr of 1.11 resulted in 89% sensitivity and 83% specific-
ity for differentiating tumor against radiotherapy-induced chronic changes [66].
Zeng et al. also explored the diagnostic effectiveness of MRS with DWI on the 
evaluation of recurrent contrast-enhancing areas at the site of treated gliomas. 
The authors found that the Cho/NAA (1.71) and Cho/Cr ratios were significantly 
higher in recurrent tumors than in regions of radiation injury, and ADC ratios 
were significantly higher in radiation injury regions than in recurrent tumors. The 
results showed that the sensitivity, specificity, and diagnostic accuracy were 94.1%, 
100%, and 96.2%, respectively [67]. In contrast, an elevated lipid-lactate peak and 
generalized decrease in other metabolites supported radiation necrosis [68]. MRS 
is limited by voxel size, often requiring the lesion to be larger than 1 cm [3] and is 
also affected by sampling errors within heterogeneous tumors and the proximity to 
the skull base.
Recently, Chuang et al. presented the results of a systematic review that 
included 397 patients included in 13 studies designed to differentiate tumor recur-
rence versus radiotherapy changes. The pooled difference in means (2.18, 95% 
CI 0.85–3.50) indicated that the average rCBV in a contrast-enhancing lesion was 
significantly higher in tumor recurrence than radiation injury (p = 0.001). Based 
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on a fixed-effect model of analysis encompassing the six studies which used Cho / 
Cr ratios for evaluation, the pooled difference in means (0.77, 95% CI 0.57–0.98) of 
the average Cho/Cr ratio was significantly higher in tumor recurrence than in RN 
(p = 0.001). In the same direction, there was a significant difference in ratios of Cho 
to NAA between recurrent tumor and necrosis (1.02, 95% CI 0.03–2.00, p = 0.044) 
[69]. At least two additional integrative studies demonstrated that MRS alone 
has moderate diagnostic performance in differentiating glioma recurrence from 
radiation necrosis using metabolite ratios like Cho/Cr and Cho/NAA ratio [70, 71]. 
Figure 2 shows the main imaging characteristics in conventional MRI (contrasted 
T1 phase), MR perfusion and MRS.
5.3 PET
Impaired BBB is considered the leading diagnostic indicator of brain tumors and 
metastases on contrast-enhanced MRI and CT. Similarly, many PET tracers that can 
identify tumor cells at various sites in the body would only reach the brain if the 
BBB is disrupted. Therefore, the development of specific tracers that do not depend 
on BBB damage, such as fluorodeoxyglucose (18F-FDG) and labeled amino acids 
(aa) that are transferred by specific transporters across the intact BBB was intro-
duced. Different studies showed that 18F-FDG is unhelpful in differentiating tumor 
progression from RN. Even though 18F-FDG alone has a low sensitivity (43%), its 
combination with other imaging techniques like MRI might increase its diagnostic 
usefulness [72]. The fact that tumoral or highly inflamed tissue might have an 
increased uptake of amino acids [73], and the relatively low uptake of normal brain 
tissue would provide a considerable tissue contrast. Compared to 201Tl, 18F-FDG is 
more specific but less sensitive to detect tumor recurrence since the former, before 
its uptake through the Na+-K+ ATPase pump, has a non-specific accumulation due 
to BBB breakdown. The latter lacks sensitivity because of the physiological uptake 
Figure 2. 
(A) Post-surgical right parietal changes due to resection of a metastatic lesion adjacent to the precentral sulcus 
with enhancement in the contrasted T1 sequence after SRS execution (compatible with RN). The lesion has an 
irregular morphology and measures 18x13x16.7 mm. (B) Decrease in all metabolites compared to the healthy 
zone, without evidence of Cho/NAA ratios greater than 2.0. There is also an increase in the peak of lactate-
lipids, indicating that it corresponds to RN. (C) In the postsurgical cavity and in the nodular lesion that is 
enhanced with contrast medium, there are low values of rCBV.
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of normal brain [74]. More specifically, in the differentiation of tumor recurrence 
and RN, 18F-FDG also has low specificity, ranging from 40 to 94%, mainly during 
the first few weeks post-therapy, with a study that showed a sensitivity of 81–86%. 
Therefore, it is recommended to perform 18F-FDG PET no less than 3 months after 
the end of RT, also because it can cause inflammatory changes that can last up to 
6 months after therapy but slowly decreases over time, for example, in the lung 
parenchyma, which will take up FDG and make it difficult to differentiate from the 
recurrent tumor [75].
Other amino acids have been studied, including fluoro-1-thymidine, fluoro-
ethyltyrosine (18F-FET), 3,4-Dihydroxy-6-18F-fluoro- l -phenylalanine (FDOPA), 
l-[Methyl- 11 C] methionine (11C-MET), 3-Deoxy-30-18F-fluorothymidine 
(18F-FLT) and carbon-11 choline. Floeth et al. compared 18F-FET performance 
with MRI and MR spectroscopy in 50 patients, showing in 34 tumoral lesions a 
mean tumor/non-tumor ratio (T/NT) of FET uptake of 2.4 ± 0.9, thus signifi-
cantly higher than non-neoplastic lesions (16 lesions; p < 0.001), with the area 
of significant 18F-FET uptake that was always included within the area of MR 
signal abnormality, which means that the latter could often be overestimating the 
extension of disease. More 30 out of 34 gliomas demonstrated an increased 18F-
FET uptake (T/NT ratio > 1.6), with an overall sensitivity and specificity for the 
distinction of tumors from non-neoplastic tissues of 88% and 88%, respectively 
[76]. Concerning RN, studies have shown the absence of 18F-FET uptake in a case 
of RN in contrast to 18F-FDG; this could be due to the absence of 18F-FET uptake 
from macrophages, which are a common inflammatory mediator usually present 
in such cases. Recently, a study performed by Radinger et al. evaluated 36 patients 
with a glioma diagnosis. They used 18F-FET vs. MRS to differentiate tumor 
progression from RN correctly. In this study, pathological assessment and clinical 
manifestations were used as confirmatory variables. A specificity of 93% and a 
sensitivity of 100% was calculated for 18F-FET after suspicion of the recurrent 
tumor revealed by MRI (this highlights the importance of combining techniques 
for better analysis) [77].
18F-FDOPA is an amino acid tracer that has been used at the beginning for the 
evaluation of movement disorders by assessing the integrity of the striatal dopa-
mine pathway. Recently, 18F-FDOPA it is studied in the imaging of brain tumors. 
In this scenario, one of the main pros of 18F-FDOPA lays in the crossing of the BBB 
thanks to a specific neutral amino acid transporter, which grants a better uptake 
ratio also because tracer accumulation does not depend on BBB breakdown [78]. In 
a non-conventional meta-analysis, Yu et al. evaluated the accuracy of 18F-FDOPA 
and compared it to 18F-FET for differentiating RN from brain tumor recurrence 
going through 48 separate studies (18F-FDOPA, n = 21; 18F-FET, n = 27), in which 
both tracer showed comparable results in terms of pooled sensitivity (85%), speci-
ficity (82%) and diagnostic odds ratio (21.7); in particular, 18F-FDOPA showed bet-
ter diagnostic accuracy in patients with glioma compared with patients with brain 
metastases and proved to be better than 18F-FET in diagnosing glioma recurrence. 
In any case, larger cohorts of patients will be needed to support these preliminary 
findings [79].
11C-MET is a PET amino acid isotope characterized by a relatively short half-life 
that in tumors determine the high density and activity of amino acid transporters. 
Instead, it can accumulate due to active transport and cell proliferation, but in RN, 
passive diffusion via BBB damage is the most probable uptake mechanism [80]. 
Therefore, the difference in terms of accumulation mechanisms could be a way to 
distinguish the two clinical settings. Concerning its role in the differentiation of 
recurrence from RN, Hustinx et al. explain the potential role of 11C-MET to dif-
ferentiate either low-grade or high-grade gliomas. 11C-MET uptake was directly 
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related to prognosis and survival in low-grade gliomas since it is increased in the 
absence of BBB breakdown, thus determining a significant advantage over CT, MRI, 
or even 18F-FDG PET.
Moreover, in the case of high-grade gliomas, 11C-MET uptake is higher than 
in low-grade tumors; therefore, it could be used for monitoring purposes to assess 
anaplastic transformation [81]. In a recent study of 18 lesions from 15 patients with 
metastatic brain tumors who underwent gamma knife radiosurgery, the authors 
showed that 11C-MET was superior in terms of both sensitivity and specificity as 
an imaging technique for differentiating RN and recurrent metastatic tumors after 
gamma-knife compared with diffusion-weighted imaging (DWI), MR permeability 
imaging and 18F-FDG. However, it is not widely available yet for clinical use due to 
its physical limitations [82]. Another study showed that 11C-MET could differenti-
ate recurrence from RN based on the PET/Gd volume ratio and the PET/Gd overlap 
ratio as these ratios were significantly lower in patients with RN than in patients 
with glioblastoma recurrence (p < 0.05) (analysis were done based on a pathologi-
cal assessment) [83].
18F-FLT is a radiolabeled analog that has been used to indicate tumor prolif-
eration since thymidine is a nucleoside encountered only in DNA; therefore, it 
reflects tissue proliferation rate. 18F-FLT transport is mediated mainly by active 
Na + −dependent carriers through nucleoside transporters (salvage thymidine 
pathway) and passive diffusion. Enslow et al. made a tracer comparison taking in 
consideration 18F-FLT kinetic parameters (18F-FLT Kimax) rather than simple 
SUV max values [18F-FLT Kimax ≥0.0165 (sensitivity 91%, specificity 75%); 
18F-FLT SUV max ≥1.34 (sensitivity 73%, specificity 75%)] and although there 
was no statistically significant difference both 18F-FDG and 18F-FLT proved to be 
accurate in the differentiation between recurrent glioma and radiation necrosis 
[84]. Unfortunately, even if dynamic kinetic modeling of 18F − FLT-PET has 
proven to be crucial and its superiority could not be demonstrated only for the 
small number of patients included in the study, due to the complexity of the 
procedure, it is unlikely that it will be broadly accepted in clinical practice. No 
single technique of PET and other imaging techniques has been shown to be able 
to differentiate recurrence from RN by itself. Based on the limitations of each 
modality, a multi-modal approach is currently used. Figure 3 shows the differ-
ences between different PET tracers for the diagnosis of RN versus conventional 
MRI and the perfusion sequence.
Figure 3. 
A. Fibrinoid necrosis or hyalinization, fibrosis of blood vessels, dystrophic calcification and an inflammatory 
infiltrate consisting predominantly of macrophages. B. Radiation induced cytologic atypia.
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6. Pathological assessment
Histopathology is currently the gold standard to diagnose tumor recurrence or 
RN. A significant difference in histologic findings exists between these two condi-
tions. Macroscopically, RN shows as a firm-like mass or sometimes as a soft cystic 
lesion. A yellow-to-brown necrotic core is usually accompanied by significant 
hemorrhage, gliosis, and tissue atrophy [85]. In the case of RN, fibrinoid necrosis, 
hemorrhage, hyalinization and, blood vessel thrombosis can be seen, with a visible 
hypoxic injury of the surrounding tissue [5]. The necrotic area is usually paucicellular, 
characterized by the presence of inflammatory ghost cells and focal perivascular 
lymphocytes, and surrounded by gliotic brain tissue corresponding mainly to GFAP-
reactive astrocytes (reactive gliosis) [86]. Inside the lesion, other cell types like foamy 
macrophages and hemosiderophages can be seen. A low nuclei-cytoplasmic ratio is 
characteristic. On the other hand, tumor recurrence shows a high cellularity with a 
Figure 4. 
Representative PET and MRI images of radiation necrosis (RN). (A) Example of an RN area by SRS performed 
in a postsurgical cavity due to metastasis of a lung adenocarcinoma located in the right precentral sulcus.  
(B) Variations between 11C-MET and 18F-FDG PET in a large area of left frontal RN after resecting a high-
grade glioma treated with IMRT. (C) FLT-PET study from the progression of a recurrent glioblastoma multiforme. 
MRI T1 Gd shows a large right frontal contrast-enhancing lesion versus FLT- PET and FDG-PET scans.
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ghost cell outline, demonstrating a high nuclei-cytoplasmic ratio. In brain metastases, 
careful examination of the blood vessels is essential as residual tumor cells might be 
seen around the Virchow Robin spaces. An immunohistochemistry panel will reveal 
the usual immunophenotype of the suspected tumor recurrence according to the 
patient’s history. Histopathological assessment is not routinely performed unless an 
invasive approach to the lesions is needed for other purposes like therapeutic inter-
ventions. Figure 4 shows the main pathological features of radiation injury, including 
cytological atypia, fibrinoid necrosis, and the marked inflammatory infiltrate.
7. Management of radiation necrosis
7.1 Observation
Since the 1970s, RN can be controlled with advanced images and left under 
observation. Wang et al. described a series of 124 patients who had radiation for 
nasopharyngeal carcinoma and developed severe imaging changes in the temporal 
lobe; among them, 28% of white matter lesions, 39% of contrast-enhanced lesions, 
and 7% of cysts regressed or resolved [87]. Since RN is not always symptomatic and 
evolutionary, it is considered that about half of the cases could be managed with 
observation, especially if the lesions are small and are located in non-eloquent areas.
7.2 Steroids
For patients with symptomatic brain RN, steroids are typically the first-line 
treatment, as they effectively reduce symptoms associated with brain edema and also 
inhibit the pro-inflammatory cascade involved in radiation injury. However, with-
drawal of corticosteroids may result in a rebound of the edema and related symptoms 
and prolonged use of corticosteroids can be associated with significant toxicity includ-
ing steroid myopathy, iatrogenic Cushing’s syndrome and glucose intolerance [88].
7.3 Bevacizumab
There have been several recent reviews addressing the use of bevacizumab 
for brain RN [89, 90] that included data from both retrospective and prospective 
studies. Lubelski et al. reported on 30 patients included in seven studies of beva-
cizumab for patients with brain RN following treatment for high-grade glioma. 
Similar to this review, all patients demonstrated a radiographic response on T1 and 
T2-weighted MRI. Out of the 23 patients for which clinical data were reported, 
16 (70%) showed an improvement. A subsequent broader review that included 
71 patients treated with bevacizumab for brain RN after treatment of any brain 
tumor across 16 studies reported radiographic improvement in 97% of patients 
and improvement in performance status in 79% of patients [89]. Therefore, these 
reviews agree around information suggesting that the radiographic response rate to 
bevacizumab is high for patients with brain RN, and this response may be associ-
ated with symptomatic or functional improvement.
A recent systemic review found only three clinical trials with pharmacological 
interventions to reduce the clinical and radiological features of brain RN [91]. The 
first one is a randomized, double-blind, placebo-controlled trial of bevacizumab 
7.5 mg/kg every three weeks for 2 cycles versus placebo tested in adults treated with 
radiotherapy for the brain or head and neck neoplasm and with radiological diagnosis 
of brain RN based on MRI criteria. Included patients were allowed to be taking corti-
costeroids before study participation, but they were required to be using a stable dose 
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for at least one week before receiving study treatment. The primary endpoint was 
the radiological response, defined as at least a 25% reduction in brain edema at six 
weeks of treatment compared with pre-treatment; this was measured as the volume 
of hyperintensity on T2-FLAIR MR images [92]. This trial reported that 100% (7/7) 
of participants on bevacizumab had a reduction in brain edema (T2 hyperintense 
volume) by at least 25% and a reduction in post-gadolinium enhancement.
In contrast, all those receiving placebo had clinical and/or radiological progres-
sion (five participants in the placebo arm experienced progressive clinical symptoms 
while two patients had radiological progression without progressive symptoms). 
Three severe adverse events were noted with bevacizumab which included aspiration 
pneumonia, pulmonary embolus, and superior sagittal sinus thrombosis [92].
The second was an open-label trial of patients treated with methylprednisolone 
500 mg intravenously for three days followed by prednisone orally on a tapering 
schedule over 30 days, as tolerated, with or without the addition of edaravone 30 mg 
orally twice daily for 14 days. Eligible patients were adults (> 18 years old) treated 
with radiotherapy at least six months before study enrollment with radiographic 
evidence of RN based on MRI features. This trial also defined response as at least 25% 
reduction in the volume of T2-hyperintensity, and the primary endpoint was evalu-
ated at three months following the start of treatment [93]. This study demonstrated a 
more significant reduction in brain edema in the edaravone plus corticosteroid group 
than in the corticosteroid alone group (mean difference was 3.03, 95%CI 0.14–5.92), 
although the result approached borderline significance (p = 0.04). There was no 
evidence of any critical difference in the reduction in post-gadolinium enhancement 
between arms (mean difference 0.47, 95% CI -0.80-1.74). Similarly, the participants 
who received the combination treatment were noted to have significantly greater 
clinical improvement than corticosteroids alone measured using the Late Effects 
Normal Tissue Task Force-Subjective, Objective, Management, Analytic (LENT-
SOMA) scale (OR 2.51, 95%CI 1.26–5.01). No differences in treatment toxicities were 
observed between arms, and no severe adverse events were reported.
Besides, one prospective non-randomized study allowed patients to choose 
between vitamin E 1000 IU twice daily for one year or no active treatment. Eligible 
cases were adults treated with radiotherapy for nasopharyngeal carcinoma with 
no evidence of recurrence for at least five years who have developed radiological 
evidence of unilateral or bilateral temporal lobe necrosis without mental impair-
ment. Unlike the two randomized studies, serial imaging was not evaluated in this 
study. Patients were assessed at baseline and one year using a battery of in-house 
and more widely utilized neuropsychological tests, including the Cantonese version 
of the Mini-Mental Status Examination (CMMSE), Hong Kong List Learning Test 
(HKLLT), Visual Reproduction subtest of the Wechsler Memory Scale III (WMS-
III VR), Category Fluency Test (CFT) and computerized Cognitive Flexibility 
Test [94]. Evaluating cognitive function in patients at baseline and after one year 
of treatment, a 5.3% improvement in global cognitive function on CMMSE was 
seen in patients who received vitamin E compared with no improvement in the 
control group (P = 0.007). Assessment of verbal learning using the Hong Kong 
List Learning Test (HKLLT) demonstrated that the treatment group had a 27.2% 
improvement at one year versus no improvement in the control group.
Similarly, improvements were seen for visual memory and recall for the group 
treated with vitamin E. There was no difference in attention, language, or executive 
function between the two groups at baseline or at one year. Corticosteroid require-
ments and adverse events to treatment were not reported in this study [94].
Another integrative study gathered the information from two prospective, seven 
retrospective, and three case report studies involving 89 patients with RN treated 
with bevacizumab [95]. In total, 93% of patients had a recorded radiographic 
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response to antiangiogenic therapy, and 6.7% had experienced RN progression. 
Seven studies (n = 73) reported mean volume reductions on gadolinium-enhanced 
T1 (mean 47%, +/− 24) and T2-weighted fluid-attenuated inversion recovery 
(FLAIR) MRI images (mean 62%, +/− 23). Pooling together the T1 and T2 MRI 
reduction rates revealed a mean of 48 (95% CI 38–59) for T1 reduction rate and 62 
(95% CI 52–72) for T2W imaging studies. Eighty-five patients presented with neu-
rological symptoms at bevacizumab exposure, since when nine (10%) had stable 
symptoms, 39 (48%) had improved, and 34 (40%) patients had complete resolution 
of their clinical impairment. Similarly, dexamethasone discontinuation or reduc-
tion in dosage was observed in 97% of patients who had recorded dosage before and 
after bevacizumab treatment [95].
Considering the use of alternative ways for the administration of bevacizumab 
in patients with RN, Dashti et al. described two pediatric patients with cerebral 
arteriovenous malformations (AVM), who presented with medically intractable 
radiation injury following stereotactic radiosurgery. They received a single 
intraarterial infusion of 2.5 mg/kg bevacizumab after hyperosmotic BBB disrup-
tion. At a mean follow-up duration of 8.5 months, the patients had a significant 
and durable clinical and radiographic response. Both cases experienced resolution 
of their previously intractable headaches and reversal of cushingoid features as 
they were successfully weaned off steroids. One of the patients regained signifi-
cant motor strength, and there was an associated greater than 70% reduction in 
cerebral edema [96].
Baroni et al. described pediatric patients’ experience from five referral centers 
that treated 26 cases of symptomatic radiation necrosis with bevacizumab. The 
mean age at diagnosis of radiation necrosis was 10.7 years, with a median time 
between the last dose of radiation and the presentation of radiation necrosis of 
3.8 months (range, 0.6–110 months). Overall, 50% of patients had an objective 
clinical improvement, with only one suffering from significant hypertension. 
Radiological benefit, defined as reduced T2/fluid-attenuated inversion recovery sig-
nal and mass effect, was observed in 50% of cases; however, this did not completely 
overlap with clinical response. Both early and late radiation necrosis responded 
equally well to bevacizumab therapy, and overall the monoclonal antibody was well 
tolerated, allowing the reduction of corticosteroid dose and/or duration [97].
7.4 Surgery
Although surgery is frequently used in clinical practice to address progressive 
resectable RN lesions, no prospective trials of surgical resection for brain RN were 
identified in this review. A retrospective series of 24 adult patients who underwent 
craniotomy and resection of contrast-enhancing lesions in the temporal lobes  
(16 unilateral and eight bilateral) following radiotherapy for nasopharyngeal 
carcinoma reported a reduction in the extent of brain edema observed on either CT 
or MRI (in those cases who had serial imaging). Only one patient required a repeat 
resection for recurrent necrosis [98]. In patients who were treated with radiosurgery, 
a retrospective series of 15 patients treated with surgical resection for RN reported 
improvement in brain edema resulting in either a partial or complete taper off 
corticosteroids as well as symptom improvement in the majority of patients [99].
7.5 Pentoxifylline and vitamin E
Pentoxifylline (PTX) is a methylxanthine derivative that decreases blood viscos-
ity, increasing blood circulation and tissue oxygenation. Vitamin E (or tocopherol) 
acts as a free-radical scavenger. In a small retrospective study of 11 patients with 
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brain RN following radiotherapy for brain metastases, meningioma, and AVMs, the 
combination of PTX and vitamin E resulted in radiological improvement in all but 
one patient, who was eventually confirmed to have tumor recurrence [100].
7.6 Hyperbaric oxygen
There are limited small retrospective case reports and case studies reporting the 
outcomes of Hyperbaric oxygen (HBO) therapy for brain RN. Pasquier et al. reported 
limited retrospective reports of HBO as part of a more extensive review of HBO 
therapy for radiation injury to all body sites. These retrospective reports suggested 
favorable responses to HBO therapy to some patients; however, no prospective data 
is available [101]. Only one single-arm study evaluating HBO’s impact on clinical 
improvement and reduction of edema in patients who develop cerebral radiation 
necrosis following gamma knife radiosurgery (GKS) (NCT02714465) was on-going.
7.7 Laser-induced thermal therapy (LITT)
Only one single-arm study of a LITT reported promising local control of 75.8% 
(13 of 15 lesions) and dramatic reductions in lesion volume to less than 10% of the 
pre-treated volume in seven of the treated lesions [102]. However, as this was a 
single-arm study with a limited number of patients, a further prospective investiga-
tion is required to compare this treatment’s effectiveness against current manage-
ment approaches. Figure 5 shows a proposed algorithm for the diagnostic and 
therapeutic approach of NR.
8. Conclusions
Despite the rising incidence of RN because of increased utilization of stereotac-
tic radiosurgery and reirradiation, there remain significant challenges in diagnosing 
Figure 5. 
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this complex brain injury. To date, there is no established standard to diagnose RN 
noninvasively. Over the past few years, there are, however, more treatment options, 
particularly with bevacizumab. More studies are needed to define who is at risk and 
how to minimize these risks; to diagnose radiation necrosis more accurately with 
imaging, blood tests, or other noninvasive techniques; and to treat these patients 
quickly before neurological signs and symptoms develop and progress.
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